NCT05578820 - Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

April 11, 2024

Study Completion Date

April 11, 2024

Conditions

SarcomaMelanomaSquamous Cell Carcinoma of Head and NeckBreast NeoplasmsUterine Cervical NeoplasmsVulvar NeoplasmsPenile NeoplasmsAnus Neoplasms

Interventions

BIOLOGICAL

Stimotimagene copolymerplasmid

Gene therapy drug, Intratumoral administration

DRUG

Ganciclovir

Antiviral drug, Intravenous administration

Trial Locations (4)

111123

GBUZ Moscow Clinical Scientific Center named after Loginov MHD, Moscow

115478

FSBI N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia, Moscow

117997

FSBI National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov of the Ministry of Health of Russia, Moscow

125284

National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow

All Listed Sponsors

lead

Gene Surgery LLC

INDUSTRY